Aethlon Medical, Inc. (AEMD)

Over the past six months, Aethlon Medical, Inc.'s stock price has decreased by 45.24%, and over the past year, it has dropped by 92.43%. In March 2026, Aethlon Medical announced that all previously outstanding pre-funded warrants had been exercised, resulting in 1,569,110 shares of common stock outstanding. In March 2026, the company engaged Maxim Group LLC to evaluate strategic opportunities, including potential partnerships, mergers, and acquisitions. Also in March 2026, Aethlon Medical advanced to the final cohort in its oncology clinical trial following a positive DSMB review. In February 2026, the company presented at the Emerging Growth Conference and announced its fiscal Q3 2026 financial results and corporate update. In November 2025, Aethlon Medical held its Second Quarter 2026 Investor Call.

Information regarding demand seasonality for Aethlon Medical, Inc.'s products and services is not readily available.

Aethlon Medical, Inc. is a medical technology company focused on developing products for diagnosing and treating life and organ-threatening diseases. The company operates in the Healthcare sector, specifically in the Medical Devices and Biotechnology industries. Their primary product is the Aethlon Hemopurifier, an immunotherapeutic device in clinical stages designed to combat cancer and eliminate life-threatening viral infections. The FDA has designated the Hemopurifier as a Breakthrough Device for treating advanced or metastatic cancer and life-threatening viruses. The company's operations are divided into Aethlon, focusing on therapeutic activities, and ESI, handling diagnostic activities.

Aethlon Medical, Inc. is headquartered in San Diego, California. The company is conducting clinical trials for its Hemopurifier in cancer patients with solid tumors in Australia and has also conducted clinical trial work in India, maintaining relationships with doctors there.

Aethlon Medical's brand reputation in the past year appears to be influenced by its ongoing clinical trial progress and strategic corporate activities. Advancing its Hemopurifier oncology clinical trial to the final cohort after a positive Data Safety Monitoring Board (DSMB) review is a positive event. Engaging Maxim Group LLC to explore strategic opportunities could enhance its market position and financial stability. Regular participation in investor calls and conferences also contributes to maintaining visibility and communication with the investment community.

Aethlon Medical, Inc. has several institutional owners and shareholders, including Ikarian Capital, LLC, Morgan Stanley, and UBS Group AG. There was a reported 88.46% drop in AEMD's institutional ownership in a recent quarter, largely due to a near-complete institutional exodus from the stock. Fintel data indicated that AEMD had only 3 institutional owners, with institutional shares (long) showing a 100.00% decrease of approximately 1.69 million shares in the most recent quarter, suggesting a significant liquidation of positions by institutions.